Showing posts with the label Gilead Sciences

Gilead and Vir Biotechnology Establish Clinical Collaboration to Explore Combination Strategies for Functional Cure for Chronic Hepatitis B Virus

IndustryPRwire - Gilead Sciences and Vir Biotechnology announced that the companies have entered into a clinical collaboration to evaluate novel therapeutic combination strategies aimed at developing…

Kite and Oxford BioTherapeutics Establish Cell Therapy Research Collaboration in Blood Cancers and Solid Tumors

IndustryPRwire - Kite, a Gilead Company and Oxford BioTherapeutics Ltd. a clinical stage oncology company with a pipeline of immuno-oncology (IO) and antibody-drug conjugate (ADC)-based therapies, a…

Kite’s Tecartus™ (KTE-X19) Granted Conditional Marketing Authorization for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma in Europe

IndustryPRwire - Kite, a Gilead Company announced that the European Commission has granted conditional marketing authorization for Tecartus™ (autologous, anti-CD19-transduced CD3+ cells; formerly KT…

Gilead Advances Oncology Portfolio With New Data From Phase 3 ASCENT Trial of Trodelvy® in Metastatic Triple Negative Breast Cancer

IndustryPRwire -- Gilead Sciences is presenting new data from the Phase 3 ASCENT trial of Trodelvy® (sacituzumab govitecan-hziy) in metastatic triple-negative breast cancer (mTNBC) at the 2020 San A…

Gilead Sciences to Acquire MYR GmbH

IndustryPRwire -- Gilead Sciences and MYR GmbH announced that the companies have entered into a definitive agreement pursuant to which Gilead will acquire MYR for approximately €1.15 billion in cash…

European Medicines Agency Validates Marketing Application for Filgotinib for the Treatment of Ulcerative Colitis

Gilead Sciences and Galapagos announced that the application for a new indication to the approved license for filgotinib 200 mg, an oral JAK1 preferential inhibitor, has been validated and is now un…

Ligand’s Captisol Technology Plays Key Role in the Manufacture of Gilead’s Veklury, the First FDA-Approved COVID-19 Treatment

Ligand Pharmaceuticals Incorporated today highlighted the company’s role in the manufacturing of Veklury® (remdesivir), Gilead Sciences ’ antiviral drug for the treatment of patients with COVID-19 r…

Gilead Sciences Completes Acquisition of Immunomedics, Inc.

Gilead Sciences today announced the completion of the previously announced transaction to acquire Immunomedics , Inc. for approximately $21 billion in the aggregate. Daniel O’Day, Chairman and Chief…

U.S. Food and Drug Administration Approves Gilead’s Antiviral Veklury® (remdesivir) for Treatment of COVID-19

Gilead Sciences today announced that the U.S. Food and Drug Administration (FDA) has approved the antiviral drug Veklury® (remdesivir) for the treatment of patients with COVID-19 requiring hospitali…

Gilead Announces New Data on Biktarvy® for the Treatment of HIV in Black Americans

Gilead Sciences announced 48-week data from the BRAAVE 2020 study, a Phase 3 clinical trial evaluating the safety and efficacy of switching to Biktarvy® (bictegravir 50 mg/emtricitabine 200 mg/tenof…

European CHMP Adopts Positive Opinion for Kite’s KTE-X19 for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma

Kite, a Gilead Company today announced that the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion on the company’s Marketing Authoriz…

Final Results of National Institute of Allergy and Infectious Diseases’ ACTT-1 Trial Published in New England Journal of Medicine Expand Clinical Benefits of Veklury® (remdesivir) for the Treatment of COVID-19

The New England Journal of Medicine today published the final results from the National Institute of Allergy and Infectious Diseases’ (NIAID) double-blind, placebo-controlled, Phase 3 ACTT-1 trial of…

Gilead Sciences Signs Joint Procurement Agreement With the European Commission for Veklury®

Gilead Sciences and the European Commission today signed a joint procurement agreement (JPA) that will enable rapid and equitable access to Veklury® (remdesivir), the first antiviral drug proven to b…
Subscribe Our Newsletter